LOM
TGTX icon

Loeb Offshore Management’s TG Therapeutics TGTX Stock Holding History

Loeb Offshore Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-16,242
Closed -$82K – 235
2013
Q3 		$82K Buy
+16,242
New +$99.3K 0.03% 211

Other funds holding TGTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SGAM
Smith Group Asset Management Dallas, Texas $1.96B AUM 43.61% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Loeb Offshore Management's TGTX Position: Q4 2013 in Review

Loeb Offshore Management sold out of TG Therapeutics (TGTX) in Q4 2013, closing a stake of 16,242 shares — an estimated $82K sold.

Loeb Offshore Management first reported a position in TGTX in Q3 2013 and held it in 1 quarter. The position peaked at $82K in Q3 2013. 45 funds tracked by Wall St. Rank hold TGTX as of Q4 2013.

  • Loeb Offshore Management reported no remaining TG Therapeutics position as of Q4 2013 after selling out during the quarter.
  • Loeb Offshore Management sold 16,242 TG Therapeutics shares in Q4 2013, an estimated $82K.
  • Loeb Offshore Management first reported a position in TG Therapeutics in Q3 2013 and held it in 1 quarter.
  • Loeb Offshore Management's TG Therapeutics position peaked at $82K in Q3 2013.
  • 45 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2013.

Based on Loeb Offshore Management's 13F filing for Q4 2013, filed 14 Feb 2014.